Right from the start, right to the finish.

Each path to healing is unique. If wounds stall, our broad portfolio of advanced wound care products help keep wounds on a healing trajectory.


Start With BBWM™

a biofilm-based wound management approach to reduce bioburden and prevent biofilm re-formation1

  • Sharp
    Debridement

  • +


Assess Wound

after 4 weeks* of PuraPly™ Antimicrobial Wound Matrix use


Healing

Continue

PuraPly Antimicrobial


Stalled

Switch

to advanced therapies based on wound type

Choose a wound type

Criteria for switching:
  • +
Bioengineered living cells

FDA approved for wound healing

Amniotic membranes

FDA regulated solely as HCT/Ps as wound coverings

Criteria for switching:
  • +
Bioengineered living cells

FDA approved for wound healing

Amniotic membranes

FDA regulated solely as HCT/Ps as wound coverings

Criteria for switching:
Amniotic membranes

FDA regulated solely as HCT/Ps as wound coverings

*Literature indicates that surface area reduction at 4 weeks is a good prognostic indicator to determine if an intervention is working.

References: 1. Phillips PL, Wolcott RD, Fletcher J, Schultz GS. Biofilms made easy. Wounds International website. www.woundsinternational.com/made-easys/view/biofilms-made-easy. Published May 17, 2010. Accessed October 12, 2017. 2. Sheehan P, Jones P, Caselli A, Giurini JM, Veves A. Percent change in wound area of diabetic foot ulcers over a 4-week period is a robust predictor of complete healing in a 12-week prospective trial. Diabetes Care. 2003;26(6):1879-1882. 3. Phillips TJ, Machado F, Trout R, Porter J, Olin J, Falanga V. Prognostic indicators in venous ulcers. J Am Acad Dermatol. 2000;43(4):627-630. 4. Gelfand JM, Hoffstad O, Margolis DJ. Surrogate endpoints for the treatment of venous leg ulcers. J Invest Dermatol. 2002;119(6):1420-1425.